HIGH-VOLUME · FEMALE-LED

etanercept Side Effects

etanercept (also sold as Enbrel) is HIGH-VOLUME in this FAERS book #2 of 524 by FAERS report count. Signature opener: FEMALE-LED - 75% of sex-coded reports are female (407,745 F / 139,055 M).

Data updated 2026-05-15

591,578
FAERS reports

FAERS voluntary reports, 2004 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.

etanercept reporting skew - 75% of sex-coded reports are female (407,745 F / 139,055 M). Volume band HIGH-VOLUME #2 of 524 by FAERS report count; caseload MEGA-CASE.

High-report extract for etanercept (Enbrel): 591,578 FAERS rows (2004-2025). Top named reactions: INJECTION SITE PAIN, RHEUMATOID ARTHRITIS, ARTHRALGIA. Outcome stamps DEATH-MARKED · HOSP-MID · FEMALE-LED. FAERS is voluntary signal detection, not incidence.

Counts from the openFDA FAERS extract (2004–2025). Stamps MEGA-CASE · DEATH-MARKED · HOSP-MID · FEMALE-LED.

INJECTION SITE PAIN leads 56,664 of 591,578 reports

INJECTION SITE PAIN
56,664
RHEUMATOID ARTHRITIS
46,175
ARTHRALGIA
44,971
PAIN
43,004
INJECTION SITE ERYTHEMA
41,016
FATIGUE
30,269
PAIN IN EXTREMITY
25,460
JOINT SWELLING
25,430
PSORIASIS
24,970
HEADACHE
24,668
INJECTION SITE SWELLING
23,258
INJECTION SITE PRURITUS
22,089
INJECTION SITE REACTION
20,860
NASOPHARYNGITIS
20,625
CONDITION AGGRAVATED
20,532
RASH
20,059
NAUSEA
19,211
MALAISE
18,592

FEMALE-LED reporters · age peak 45-64

Female-led reporters (75% of sex-coded rows)

Female 407,745 (74%)
Male 139,055 (25%)
Unknown 1,013

Age peak 45-64 (205,107 reports)

0-17 12,226 (3%)
18-44 77,830 (20%)
45-64 205,107 (52%)
65-74 70,618 (18%)
75+ 30,149 (8%)

FAERS filings rising toward 2025

2004 2025

Reactions in Death Reports

Death appears on 16,504 reports (2.8% - MARKED). Reactions below co-occur in those rows only.

Reaction Reports
DEATH 6,230
FATIGUE 2,250
RHEUMATOID ARTHRITIS 2,104
JOINT SWELLING 2,030
ARTHRALGIA 2,003
PAIN 1,998
RASH 1,975
HYPERTENSION 1,973
GENERAL PHYSICAL HEALTH DETERIORATION 1,935
INFUSION RELATED REACTION 1,928
HEPATIC ENZYME INCREASED 1,903
HEADACHE 1,879
GLOSSODYNIA 1,869
SYSTEMIC LUPUS ERYTHEMATOSUS 1,867
HAND DEFORMITY 1,856
DIARRHOEA 1,836
PNEUMONIA 1,819
TYPE 2 DIABETES MELLITUS 1,818
VOMITING 1,811

Reactions in Hospitalization Reports

Hospitalization mid-share (65,552, 11.1%). Co-reported reactions:

Reaction Reports
RHEUMATOID ARTHRITIS 8,061
ARTHRALGIA 7,585
PAIN 7,345
PNEUMONIA 5,567
FATIGUE 5,526
CONDITION AGGRAVATED 5,316
JOINT SWELLING 5,191
ARTHROPATHY 4,798
RASH 4,702
NAUSEA 4,305
INFECTION 4,275
HEADACHE 4,133
MALAISE 4,057
DYSPNOEA 4,028
PYREXIA 4,016
SYNOVITIS 3,999
PAIN IN EXTREMITY 3,991
HYPERSENSITIVITY 3,974
How to read etanercept FAERS figures (MEGA-CASE · DEATH-MARKED · HOSP-MID)

FAERS holds 591,578 voluntary reports linked to etanercept (Enbrel), 2004-2025. Death is listed on 16,504 (2.8%). Hospitalization appears on 65,552 (11.1%). Top co-reported indication: Rheumatoid Arthritis.

MEGA-CASE books overweight common drugs and loud reporting cultures; FEMALE-LED is the page opener, not a per-patient risk.

Read with etanercept

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.